🗞️ Daily Business Brief – NOV 25,2025
- India–EU FTA – Both sides reaffirm commitment to conclude Free Trade Agreement by end-2025; accelerate talks on Investment Protection & Geographical Indications: MEA.
- Tata Motors PV – Targets 20–25% SUV market share boost with upcoming Sierra, says MD.
- Bharti Airtel Block Deal – Indian Continent may sell up to 3.43 crore shares (0.56%); deal size $806M; floor price ₹2,096.7/share.
- Jayant Infratech – Wins ₹162 crore EPC contract from Konkan Railway.
- NCC – Receives ₹2,063 crore order from Assam Govt for expansion of Gauhati Medical College & Hospital.
- HCLTech–AWS – Partners to roll out autonomous, AI-powered solutions for financial institutions.
- Vishal Mega Mart – Promoter Kedaara Capital may sell another 13% stake via block deal; willing to offer discount.
- Govt on Tobacco Cess – Multiple options under study to replace compensation cess; no final decision yet. Cess (5%–290%) to continue until back-to-back loans are repaid.
- Spandana Sphoorty – Appoints Venkatesh Krishnan as MD & CEO for 3 years starting Nov 27, 2025.
- TruAlt Bioenergy – Says sustainable aviation fuel plant may add up to ₹2,200 crore annual revenue.
- Tata Motors PV – Launches Sierra at an introductory price of ₹11.49 lakh in Mumbai.
- Anand Rathi Wealth – Infuses GBP 499,900 into Anand Rathi Wealth UK.
- Bliss GVS Pharma – Incorporates Theralife Pharma entity in Kenya.
- India–Canada – To begin Free Trade Agreement discussions soon, says Piyush Goyal.
- India–Israel – To begin Free Trade Agreement discussions soon, says Piyush Goyal.
- Piramal Finance – On track to meet FY26 guidance; H1 consolidated PAT at ₹603 crore; Growth AUM +37% YoY, above FY26 target; total AUM +22% YoY.
- EU–India Dialogue – Foreign policy & security dialogue held on Nov 18–19; both sides reaffirm aim to conclude FTA by year-end.
- Oil Futures – Extend losses following reports related to Ukraine peace deal.
- Bandhan Bank – Chief of Internal Vigilance, P. Ramaswamy, resigns.
- Zydus Lifesciences – Receives USFDA final approval for Verapamil Hydrochloride Extended-Release tablets.
🔔 Stay tuned for daily insights into India Inc, markets & macro stories!
